Retatrutide, also known as LY3437943 or LY-3437943, is a synthetic research peptide studied for activity across the glucagon, GIP, and GLP-1 receptor pathways
Suspected adverse reactions to any medicine, including unlicensed products, should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app
For eligible adults, its a simple way to explore GLP-1 therapy with medical guidance built in from the start
For people who want or need a prescribed medication, Tirzepatide is the pragmatic choice
Research-grade peptides are available from Canadian suppliers that provide third-party testing certificates, proper storage, and shipping from within Canada
For people who have had a heart attack or stroke, there is no current data showing retatrutide is unsafe, but there is also no dedicated cardiovascular outcomes trial yet to confirm safety in that population